Company news
Impedimed Limited (ASX:IPD) news
Impedimed Limited news releases on 6ix. Latest, Aug 26, 2020: Appendix 4E for year ended 30 June 2020
Press releases — page 3
Appendix 4E for year ended 30 June 2020
August 25, 2020
Appendix 4C - Quarter ended 30 June 2020
July 27, 2020
Scripps Collaboration Preps SOZO for Heart Failure Launch
July 22, 2020
Response to ASX Price Query
May 22, 2020
ImpediMed Secures US Government COVID-19 CARES Act Loan
May 6, 2020
Completion of Retail Entitlement Offer
April 27, 2020
NSW Health Expands SOZO Use for Lymphoedema Prevention
April 20, 2020
Independent BIS RE-AIM Analysis to be Released at ASCO 2020
April 19, 2020
Change in substantial holding
April 16, 2020
Appendix 4C - Quarter ended 31 March 2020
April 15, 2020
ImpediMed Releases Heart Failure and Renal Disease Software
April 14, 2020
Successful Completion of $10m Institutional Portion of Offer
April 2, 2020
Prospectus
April 1, 2020
ImpediMed Secures Order from Large US Oncology Care Network
March 31, 2020
New National Purchasing Agreement for Lymphoedema Prevention
March 22, 2020
Baylor Scott & White Expands SOZO Use with New iOS Software
March 20, 2020
Appendix 4D and Interim Financial Report (Signed)
February 19, 2020
NCCN Guidelines for Breast Cancer Updated for Lymphoedema
February 9, 2020
Appendix 4C - Quarter ended 31 December 2019
January 21, 2020
FDA 510(k) Clearance-Protein Calorie Malnutrition Assessment
November 27, 2019
Investor Presentation - Annual General Meeting
November 10, 2019
Appendix 4C - Quarter ended 30 September 2019
October 29, 2019
Lymphoedema Prevention Program Announced
October 22, 2019
Appendix 4E for year ended 30 June 2019
August 20, 2019
Appendix 4C - Quarter ended 30 June 2019
July 30, 2019
Completion of Entitlement Offer
July 19, 2019
Offer Booklet - Entitlement Offer
June 27, 2019
A$13.9m Fully Underwritten Entitlement Offer Announced
June 26, 2019
PREVENT Interim Results - Practice-Changing
May 5, 2019
ASBrS Releases PREVENT Abstract
May 2, 2019
Appendix 4C - Quarter ended 31 March 2019
April 29, 2019
US Investor Presentation
April 17, 2019
S&P DJI Announces March 2019 Quarterly Rebalance
March 7, 2019
Appendix 4C - Quarter ended 31 December 2018
January 29, 2019
PREVENT Trial accepted for Publication and Presentation
January 28, 2019
Ascension National Purchasing Agreement Received
January 16, 2019
Appendix 4C - Quarter ended 30 September 2018
October 16, 2018
ImpediMed Completes Asset Sale of XiTRON Technologies, Inc.
October 11, 2018
S&P DJI Announces September 2018 Quarterly Rebalance
September 6, 2018
Response to ASX Aware Query
August 24, 2018
L-Dex Suggested as a New Standard of Care
August 23, 2018
PREVENT Trial Results Published - Outstanding Initial Data
August 22, 2018
Appendix 4C - Quarter ended 30 June 2018
July 22, 2018
Appendix 4C - Quarter ended 31 March 2018
April 25, 2018
Interim Results of PREVENT Trial
April 19, 2018
US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment
April 17, 2018
ImpediMed & Sharp HealthCare Sign Agreement for SOZO
March 7, 2018
Appendix 4C - Quarter ended 31 December 2017
January 29, 2018
US FDA 510(k) Clearance Issued for CHF Monitoring with SOZO
December 26, 2017
L-Dex Abstracts to be Presented at Breast Cancer Symposium
November 8, 2017